Cytokinetics, Incorporated

Good afternoon and welcome, ladies and gentlemen, to Cytokinetics' third quarter 2023 conference call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the company's request, we will open the call for questions and answers after the presentation. We will allow for one question per participant. I will now turn the call over to Diane Wiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.

Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Thaddee Malik, EVP of R&D, will provide updates related to Affie-Campton, focused to Sequoia HCM and Forest HCM. Stuart Kupfer, SVP and Chief Medical Officer, will provide additional updates for Affie-Campton relating to Acacia HCM and Maple HCM, and we'll also discuss our early stage pipeline, inclusive of CK586 and CK136. Andrew Kalos, EVP and Chief Commercial Officer, will discuss commercial readiness activities for ASCII-Campton. Robert Wong, VP and Chief Accounting Officer, will provide a financial overview of the past quarter, and Ching Jha, SVP and Chief Financial Officer, will discuss our financial outlook and corporate development strategies. And finally, Robert Blum will provide closing comments and review upcoming expected key milestones. Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts, and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements. Additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements is contained in our SEC filings, including our current report regarding our third quarter 2023 financial results filed on Form 8K that was furnished to the SEC today. We undertake no obligation to update any forward-looking statements after this call. And now I will turn the call over to Robert.

Thank you, Diane, and thanks for joining us on the call today. I'm pleased with the progress we made in the third quarter, particularly focused to AFI-Campden, our top priority, and with emphasis on the execution of Sequoia HCM and advancement of its broad development program. Thanks to the diligence and dedication of our teams, we remain on track to share top line results from Sequoia HCM in late December. While this timeline is admittedly tight, we're confident due to the superb organization and oversight of Sequoia HCM by our clinical operations and statistical teams. Like all of you on the call, we're eager to see these top line results. As Fadi will elaborate, we have strong conviction that the top line results from Sequoia HCM will meet our high expectations for both safety and efficacy based on the patient population enrolled in Sequoia HCM, as well as the unique attributes of Affy-Campden. If Sequoia HCM meets our expectations on both efficacy and safety, we expect it may contribute to expansion of the cardiac myosin inhibitor or CMI category on both accounts. Simultaneously, during the quarter, we continue to build our specialty cardiology franchise by advancing the ongoing clinical trials in the development program for Affy-Campden as well as earlier stage clinical research. With enrollment underway in both Maple HCM and Acacia HCM, we foresee a near-term future with multiple catalysts for Afikampton. And rounding out our specialty cardiology franchise are CK586, a second cardiac myosin inhibitor, and CK136, a cardiac troponin activator, on which Stuart will provide an update. Our cash position at the end of the quarter represents over 18 months of cash runway based on our 2023 net cash burden guidance. Importantly, as is our practice for both financial health and prudent planning, we're gating spending through the readout of top line results of Sequoia HCM and we're judiciously focusing our current spending on activities related to our top priorities. Again, with focus to AFI Campton and a critical eye towards cost efficiencies. Today, you'll hear about the continued progress we made during the quarter and what to expect through the end of the year. As we approach 2024, and as you heard a few weeks ago at our Investor and Analyst Day, cytokinetics remains laser focused to delivering on the promise of AFI Campton as well as to advancing our earlier stage pipeline as we build our specialty cardiology franchise for the potential benefit of both patients and shareholders. And with that, I'll turn the call over to Fatty.